

RECEIVED  
CENTRAL FAX CENTER



HAMRE, SCHUMANN,  
MUELLER & LARSON, P.C.

NOV 27 2007

AN INTERNATIONAL INTELLECTUAL PROPERTY LAW FIRM

FAX TRANSMISSION November 27, 2007

TO: Mail Stop: AMENDMENT  
Examiner: A. GUSSOW  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FROM: Bryan A. Wong

OUR REF: 09548.1019USWO

TELEPHONE: (612) 455.3800

Total pages, including cover letter: 11


PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: **AMENDMENT UNDER 37 C.F.R. §1.111 (10 pages)**

Applicant: SUN  
Serial No.: 10/571836  
App. Filed: March 15, 2006  
Group Art No.: 1643

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By:   
Name: Bryan A. Wong  
Reg. No.: 50,836

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Tracy Kimmel

Signature 

  
Date

225 SOUTH SIXTH STREET · SUITE 2650 · MINNEAPOLIS · MN 55402  
TEL 612.455.3800 · FAX 612.455.3801  
WWW.HSML.COM · MAIL@HSML.COM

RECEIVED  
CENTRAL FAX CENTER

NOV 27 2007

S/N 10/571,836

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SUN	Examiner:	A. GUSSOW
Serial No.:	10/571,836	Group Art Unit:	1643
Filed:	March 15, 2006	Docket No.:	09548.1019USWO
Title:	A SUPERANTIGEN FUSION PROTEIN FOR ANTI-CANCER THERAPY AND METHODS FOR THE PRODUCTION THEREOF (AS AMENDED)		

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on November 27, 2007.

By:

Name: Tracy Khamel

Mail Stop: AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**AMENDMENT UNDER 37 C.F.R. §1.111**

Dear Commissioner:

In response to the non-final Office Action mailed August 27, 2007, please amend the above-identified application as indicated herein.

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** begin on page 3 of this paper and a Listing of Claims is provided.

**Remarks** begin on page 7 of this paper.